Docking studies using mef 2a and myeloperoxidase as target proteins for myocardial infarction

Cardiovascular disease is a class of diseases that involve the heart or blood vessels. They remain the biggest cause of deaths worldwide, though over the last two decades, cardiovascular mortality rates have declined in many high-income countries, it is still a major concern in today’s society. Cardiovascular diseases are the number 1 cause of death globally. About 17.5 million people died from CVDs in 2012, representing 31% of all global deaths. Of these deaths, an estimated 7.4 million were due to Myocardial Infarction and 6.7 million were due to stroke. Myocardial infarction occurs due to the interruption of blood supply to a part of the heart, causing heart cells to die. This is most commonly due to occlusion of a coronary artery by a blood clot which results in ischemia and emanates oxygen shortage, finally leading to the death of cardiac muscle tissue (Myocardium). There are various drugs that can prevent Myocardial Infarction like Warfarin, Aspirin, Clopidogrel etc. By using bioinformatics as a basic tool we can understand how effective these drugs are in suppressing and counter act the protein targets like responsible for Myocardial Infarction. Docking studies are performed with respect to target and various drugs. These results help us in understanding the effectiveness of each drug on these protein targets.